In light of this, it is conceivable that the ZFAS1/miR-150/AIFM2 axis could serve as a more robust diagnostic and prognostic biomarker for HCC patients, surpassing the utility of ZFAS1 alone or the ZFAS1/miR-150 axis. Here, AIFM2 is linked to hepatocellular carcinoma.